NYXH

Nyxoah SA (NYXH) | Rumor.io

Nyxoah SA

NYXH

Attention (50-day avg)0%

Attention rank (50-day avg)#3,039

Bullish sentiment (50-day avg)90%

Price to earnings ratio-0.69

Market capitalization161.9M

Earnings per share-2.49

Dividend yield (TTM)—

Revenue (annual)10M

Net income (annual)-90.1M

Social

What share of all stock conversation is about NYXH?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% +0	0% 0

Sep 3

Nyxoah S.A.'s Genio sleep apnea system achieved a 77.2% response rate at 12 months in a pivotal trial, with no device-related serious adverse events.
The company plans to seek expanded U.S. approval for its system to treat Complete Concentric Collapse patients, a population currently contraindicated for commercially available treatments.
Nyxoah's stock price surged 12% on the news, with 1.7M shares traded, and the company's market capitalization is now at approximately $1.74 per share.

Generated by AI

Sentiment

Of the messages about NYXH that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100%	87.5% -12.5	92.19% +8.12
Bearish	0%	0%	12.5% new	7.81% -8.12

Apr 8

$NYXH is expected to release earnings on or before May 10th, potentially leading to a 100-170% gain.
Nyxoah has a strong growth story with EU and FDA backing, a low float, and a significant ATM raise, making it a promising MedTech stock.
$NYXH has been upgraded to a Buy rating by HC Wainwright & Co. with a target price of $15.

Generated by AI

Topics

Of the messages about NYXH that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	50%	92.43%
Technical Analysis	0%	0%	50%	2.96%
Analysts	0%	0%	0%	2.3%
Controversies	0%	0%	0%	1.64%
Earnings	0%	0%	0%	0.66%
Macro	0%	0%	0%	0%

Aug 11

$NYXH shares are trading higher after the company announced it received FDA approval for the Genio system for the treatment of obstructive sleep apnea.
FDA approval of the Genio system is expected to lead to a 73% revenue increase, with analysts projecting a commercial launch following further review by the FDA.
Nyxoah's preliminary Q2 revenue was EUR 1.3M, with operating expenses at EUR 20.7M.

Generated by AI

Community

Of the messages about NYXH, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	50%	33.33%	13.16%	17.24%
Newcomers	50%	66.67%	86.84%	82.76%

Aug 18

Newcomers are focused on the FDA approval of the Genio system, which has validated the technology and opened the US market for Nyxoah.
The company's revenue has seen significant growth, with a 74% year-over-year increase to €1.3M in Q2, driven by the FDA approval and commercial launch of the Genio system.
The Q2 earnings report highlights an operating loss of €19.9M, a decrease in gross margin to 63.4%, and a cash runway that is a new hurdle for the company.

Generated by AI

News

Nyxoah Names Liam Kelly as Chief Executive

Nyxoah (NYXH) appointed Liam Kelly as chief executive officer, starting Oct. 1, succeeding Olivier T

1d agoYahoo Finance

Nyxoah (NYXH) Begins BREATHE Study. Can Real-World Evidence Drive Genio Adoption?

Nyxoah SA (NASDAQ:NYXH) announced the first patient implantation in BREATHE on September 7. The prospective, single-arm U.S. post-approval study will evaluate Genio hypoglossal-nerve stimulation in adults aged 22 or older with moderate to severe obstructive sleep apnea for whom standard-care treatments have failed, cannot be tolerated, or are unsuitable. Plans call for up to 229 […]

19d agoYahoo Finance

Nyxoah Stock Down Despite First Genio Implant in U.S. BREATHE Trial

NYXH initiates its U.S. BREATHE study with the first Genio implant, advancing long-term clinical evidence following FDA approval.

21d agoYahoo Finance

Also Discussed

Investors talking about NYXH also mention

#	Name	Attention
1	Spruce Biosciences, Inc.SPRB	0%0
2	USCF Midstream Energy Income FundUMI	0%new
3	Inspire Medical Systems, Inc.INSP	0.01%new
4	Incannex Healthcare Inc.IXHL	0.01%0
5	MDxHealth SAMDXH	0%0
6	Viridian Therapeutics Inc.VRDN	0%0
7	Galapagos NV American Depositary ReceiptGLPG	0%0
8	argenx SE American Depositary ReceiptARGX	0%0
9	Artisan Partners Asset Management IncAPAM	0%0
10	Avalo Therapeutics, Inc.AVTX	0%0

Nyxoah SA

Healthcare
Medical Devices

Nyxoah SA is a medical technology company focused on developing and commercializing solutions for obstructive sleep apnea, a common sleep-disordered breathing condition. Nyxoah’s lead product is the Genio system, a patient-centered hypoglossal neurostimulation therapy designed to help treat moderate to severe obstructive sleep apnea. The company operates in the healthcare equipment and neuromodulation space, serving a medical market that relies on minimally invasive technologies to address chronic respiratory and sleep-related disorders. Nyxoah SA is headquartered in Mont-Saint-Guibert, Belgium, and its current business centers on bringing sleep apnea treatment alternatives to clinical practice through its proprietary Genio platform.

Website

Location

Rue Edouard Belin 12

Mont-Saint-Guibert, MI, 1435

Belgium

Social

What share of all stock conversation is about NYXH?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% +0	0% 0

Sep 3

Nyxoah S.A.'s Genio sleep apnea system achieved a 77.2% response rate at 12 months in a pivotal trial, with no device-related serious adverse events.
The company plans to seek expanded U.S. approval for its system to treat Complete Concentric Collapse patients, a population currently contraindicated for commercially available treatments.
Nyxoah's stock price surged 12% on the news, with 1.7M shares traded, and the company's market capitalization is now at approximately $1.74 per share.

Generated by AI

Sentiment

Of the messages about NYXH that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100%	87.5% -12.5	92.19% +8.12
Bearish	0%	0%	12.5% new	7.81% -8.12

Apr 8

$NYXH is expected to release earnings on or before May 10th, potentially leading to a 100-170% gain.
Nyxoah has a strong growth story with EU and FDA backing, a low float, and a significant ATM raise, making it a promising MedTech stock.
$NYXH has been upgraded to a Buy rating by HC Wainwright & Co. with a target price of $15.

Generated by AI

Topics

Of the messages about NYXH that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	50%	92.43%
Technical Analysis	0%	0%	50%	2.96%
Analysts	0%	0%	0%	2.3%
Controversies	0%	0%	0%	1.64%
Earnings	0%	0%	0%	0.66%
Macro	0%	0%	0%	0%

Aug 11

$NYXH shares are trading higher after the company announced it received FDA approval for the Genio system for the treatment of obstructive sleep apnea.
FDA approval of the Genio system is expected to lead to a 73% revenue increase, with analysts projecting a commercial launch following further review by the FDA.
Nyxoah's preliminary Q2 revenue was EUR 1.3M, with operating expenses at EUR 20.7M.

Generated by AI

Community

Of the messages about NYXH, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	50%	33.33%	13.16%	17.24%
Newcomers	50%	66.67%	86.84%	82.76%

Aug 18

Newcomers are focused on the FDA approval of the Genio system, which has validated the technology and opened the US market for Nyxoah.
The company's revenue has seen significant growth, with a 74% year-over-year increase to €1.3M in Q2, driven by the FDA approval and commercial launch of the Genio system.
The Q2 earnings report highlights an operating loss of €19.9M, a decrease in gross margin to 63.4%, and a cash runway that is a new hurdle for the company.

Generated by AI

Nyxoah SA

Social

Sep 3

Apr 8

Aug 11

Aug 18

Nyxoah Names Liam Kelly as Chief Executive

Nyxoah shares fall after CFO departure announcement

Nyxoah announces CFO transition, reaffirms 2026 guidance

Cantor Fitzgerald reiterates Nyxoah stock Overweight rating at $6

Nyxoah (NYXH) Begins BREATHE Study. Can Real-World Evidence Drive Genio Adoption?

Nyxoah Stock Down Despite First Genio Implant in U.S. BREATHE Trial

Also Discussed

Nyxoah SA

Company Information

Location

Nyxoah Names Liam Kelly as Chief Executive

Nyxoah shares fall after CFO departure announcement

Nyxoah announces CFO transition, reaffirms 2026 guidance

Cantor Fitzgerald reiterates Nyxoah stock Overweight rating at $6

Nyxoah (NYXH) Begins BREATHE Study. Can Real-World Evidence Drive Genio Adoption?

Nyxoah Stock Down Despite First Genio Implant in U.S. BREATHE Trial

Also Discussed

Social

Sep 3

Apr 8

Aug 11

Aug 18